First in it's Class, One of a kind drug with close to 400,000 PDP patients that will need treatment in the USA sooner or later, 1.6 Mill PD patients in the EU, not to mention Off Label RX. It will be the ONLY drug indicated FOR PDP and insurance companies will have little choice but to pay for it. The alternatives tend to increase the risk for side effects and are not indicated for PDP. It is the defining treatment to keep the patients stable and out of a very expensive " Dementia " Skilled Nursing Facility (SNF). Not all SNF's will accept " Dementia " patients. So you smart guys/gals out there take out your calculators ...I can't count that high.
For the newbies, thanks to the.croupier. Thank you.
1. Filing of the NDA (New Drug Application NUPLAZID™ = pimavanserin) in the first quarter of 2015.
2. 60 days for the FDA (Food and Drug Administration ) to accept the application.
3. Upon potential acceptance, FDA could also grant priority review.
4. With priority review, six months pdufa date (Prescription Drug User Fee Act ), without, 10 months.
5. Sleep disturbance trial for PDP (Parkinson's Disease Psychosis ) patients to commence in the first half of 2015.
6. EU ( European Union ) filing 6- 9 months post FDA filing, so around 3rd quarter.
7. Potential top line ADP (Alzheimer's Disease Psychosis ) in fourth quarter of 2015 or around end of 2015.
8. Schizophrenia maintenance trial to commence 2nd half of 2015.
9. More information on Pima ( NUPLAZID™ =pimavanserin) for Autism 2015.
When these morons hate me and come up with their impostor names...it makes my day worth it. I love it and just place their butts on Ignore and never have to deal with them again. THEY HATE BEING IGNORED. Most of these fools like the Village Idiot are over extended shorts or dimwits who sold their shares and trying to buy them back. So to all have a great day, 2015 will be The year of Acadia Pharmaceuticals.
1,000,000 PD patients in the USA, of which 40% will get PDP at some point. Consider just 10% penetration - 400,000 PDP patients x 0.1 = 40,000 patients . Each at $14,600/yr, - 40,000 x 14,600 = $584,000,000/yr- Thats with only 10% of the USA market alone. And Acadia has the WORLD WIDE RIGHTS TO PIMA, FIRST IN ITS CLASS-ONE OF A KIND.
....and all the longs have to do is HOLD, let the newbies and shorts do the heavy lifting. LMAO
Acadia Pharmaceuticals Incorporated
Daily Short Sale Volume
Short Interest (Shares Short)
Days To Cover (Short Interest Ratio)
Short Percent of Float
So with 5.2 mill AD patients, @ 25% that's 1.3 mill ADP patients . Figure PIMA gets 20% penetration that's 260,000 patients, at $30/per day (conservative guess of cost per day ) that's $7.8 mill per DAY. x 365 d per year = $ 2.847 BILLION per year. WOW !
As far as AD goes there are 5.2 million patients in the USA and 25-50% will get ADP. That is one heck of a lot of patients that will need treatment. So good ADP data will send this stock to ? Can you even calculate the yearly revenues ? OMG
Oh don't forget he's a real genius -cut and paste anything he sees on that "reliable" place Investor Village where he is affectionately known as the "Village Idiot ". He said he is a long...sure. Most likely he is SHORT or he sold his shares and trying his best to get back in lower.............BINGO. I mean if his I.Q. was 60+ he should have know there was something wrong with that article and would have just ignored it. Par for the Village Idiot, hysterical .... " The sky is falling the sky is falling..." ROTFLMFAO.
A little on edge aye. I guess I would be too if I was about to lose big money like you MORON. ROLMFAO
I understand some think a Cramer recommendation is a kiss of death...but here's my thinking on this. If he is going to give a bullish recommendation on ACAD then most likely The Street is not going to release their typical " party is over Hit Piece ". And could be The Street might give positive mention soon.
Interesting article by Forbes - PHARMA & HEALTHCARE 12/15/2014 @ 9:34AM 2,544 views
" Biotech Entrepreneur Tony Coles Takes Aim At Parkinson's And Alzheimer's ". Looks like Lindquist Lab and ACAD would be a good match.
This is excellent planning by a great management. These guy are running on all 8 cylinders. When Nuplazid gets approved the sales force will hit the ground running.
You have to believe in the company... not the share price.